U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H9N3.2ClH
Molecular Weight 184.067
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HISTAMINE DIHYDROCHLORIDE

SMILES

Cl.Cl.NCCC1=CNC=N1

InChI

InChIKey=PPZMYIBUHIPZOS-UHFFFAOYSA-N
InChI=1S/C5H9N3.2ClH/c6-2-1-5-3-7-4-8-5;;/h3-4H,1-2,6H2,(H,7,8);2*1H

HIDE SMILES / InChI

Molecular Formula C5H9N3
Molecular Weight 111.1451
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Histamine is a depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and a centrally acting neurotransmitter. Phosphate salt of jistamine was used as a diagnostic aid for evaluation of gastric acid secretory function. In addition, this compound is used as a positive control in evaluation of allergenic (immediate hypersensitivity or "Type I") skin testing. In addition, histamine is being studied for treatment of multiple sclerosis. It was approved, that histamine physiological functions are mediated by four 7-transmembrane G protein-coupled receptors (H1R, H2R, H3R, H4R) that are all targets of pharmacological intervention. The receptors display molecular heterogeneity and constitutive activity. H1R antagonists are long known antiallergic and sedating drugs, whereas the H2R led to the development of H2R-antagonists that revolutionized stomach ulcer treatment. The H3R is an auto receptor and heteroreceptor providing negative feedback on histaminergic and inhibition on other neurons. The H4R occurs on immuncompetent cells and the development of anti-inflammatory drugs is anticipated.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
HISTAMINE PHOSPHATE

Approved Use

Indications and Usage Uses temporarily relieves symptoms due to sinus discomforts associated with inflamed sinuses, hay fever or upper respiratory allergies: sinus pain and pressure runny nose sinus headaches sore throat nasal congestion dry mucus membranes sneezing itchy, burning eyes Reference image sinus.jpg

Launch Date

1939
Primary
Unknown

Approved Use

Unknown
Diagnostic
HISTAMINE PHOSPHATE

Approved Use

Histamine phosphate is indicated as a diagnostic aid for evaluation of gastric acid secretory function. Anacidity (achlorhydria) in response to histamine may indicate pernicious anemia, atrophic gastritis, adenomatous polyps of stomach, or gastric carcinoma. Gastric hypersecretion in response to histamine may indicate duodenal ulcer or the Zollinger-Ellison syndrome.

Launch Date

1939
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
39 nM
1 mg single, subcutaneous
dose: 1 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
HISTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1877 nM × min
1 mg single, subcutaneous
dose: 1 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
HISTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12 min
1 mg single, subcutaneous
dose: 1 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
HISTAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
0.03 mg single, intravenous
Highest studied dose
Dose: 0.03 mg
Route: intravenous
Route: single
Dose: 0.03 mg
Sources:
unhealthy
n = 4
Health Status: unhealthy
Condition: asthma
Sex: M
Population Size: 4
Sources:
0.2 mg single, intramuscular
Highest studied dose
Dose: 0.2 mg
Route: intramuscular
Route: single
Dose: 0.2 mg
Sources:
unhealthy
n = 1
Health Status: unhealthy
Condition: asthma
Sex: M
Population Size: 1
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Diesel exhaust particulates upregulate histamine receptor mRNA and increase histamine-induced IL-8 and GM-CSF production in nasal epithelial cells and endothelial cells.
1999 Jan
Involvement of glutamate in transmission of afferent constrictive inputs from the airways to the nucleus tractus solitarius in ferrets.
2000 Apr 12
Identification of a histamine H(3)-like receptor in the zebrafish (Danio rerio) brain.
2000 Aug
Possible contribution of stem cell factor in psoriasis vulgaris.
2000 Dec
Histamine H(3) receptors depress synaptic transmission in the corticostriatal pathway.
2001
Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids.
2001 Feb
Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial.
2001 Feb
No correlation between wine intolerance and histamine content of wine.
2001 Feb
Acquisition and alteration of adhesion molecules during cultured human mast cell differentiation.
2001 Feb
Inhibitory action of water soluble fraction of Terminalia chebula on systemic and local anaphylaxis.
2001 Feb
Chronic tobacco smoke exposure increases airway sensitivity to capsaicin in awake guinea pigs.
2001 Feb
A human tissue-engineered vascular media: a new model for pharmacological studies of contractile responses.
2001 Feb
Ontogeny of modulatory inputs to motor networks: early established projection and progressive neurotransmitter acquisition.
2001 Feb 15
The activation of synovial mast cells: modulation of histamine release by tryptase and chymase and their inhibitors.
2001 Feb 2
Food-deprived activity stress decreased the activity of the histaminergic neuron system in rats.
2001 Feb 9
Comparison of montelukast and fexofenadine for chronic idiopathic urticaria.
2001 Jan
Preclinical profile of the monodisperse iodinated macromolecular blood pool agent P743.
2001 Jan
Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis.
2001 Jan
The treatment of rhinovirus infections: progress and potential.
2001 Jan
Inhibition by glucocorticoids of the mast cell-dependent weal and flare response in human skin in vivo.
2001 Jan
Effect of the long-acting tachykinin NK(1) receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets.
2001 Jan
Effects of cetirizine and epinastine on the skin response to histamine iontophoresis.
2001 Jan
Acidification of formula reduces bacterial translocation and gut colonization in a neonatal rabbit model.
2001 Jan
Regulatory effect of histamine H1 receptor antagonist on the expression of messenger RNA encoding CC chemokines in the human nasal mucosa.
2001 Jan
Role of kinins in seasonal allergic rhinitis: icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen.
2001 Jan
Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy.
2001 Jan
Expression and biological significance of Ca2+-activated ion channels in human keratinocytes.
2001 Jan
Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s).
2001 Jan
Neurotransmitter release from bovine adrenal chromaffin cells is modulated by capacitative Ca(2+)entry driven by depleted internal Ca(2+)stores.
2001 Jan
Identification of rat H3 receptor isoforms with different brain expression and signaling properties.
2001 Jan
delta-opioid receptors inhibit neurogenic intestinal secretion evoked by mast cell degranulation and type I hypersensitivity.
2001 Jan 1
Luminal Nalpha-methyl histamine stimulates gastric acid secretion in duodenal ulcer patients via releasing gastrin.
2001 Jan 26
Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity.
2001 Jan 8
Approaches to healing and prophylaxis of nonsteroidal anti-inflammatory drug-associated ulcers.
2001 Jan 8
Complement-dependent immune complex-induced bronchial inflammation and hyperreactivity.
2001 Mar
Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease.
2001 Mar 2
Glycine receptor mediated responses in rat histaminergic neurons.
2001 Mar 2
Correlation between neutral endopetidase (NEP) 3.4.24.11 in serum and the degree of the bronchial hyperreactivity.
2001 Mar 2
Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanisms.
2001 Mar 30
Transcriptional activation of the rat vesicular monoamine transporter 2 promoter in gastric epithelial cells: regulation by gastrin.
2001 Mar 9
Patents

Sample Use Guides

The skin in the test area should be cleansed with alcohol and air dried. The histamine control skin test solution should be placed at the same site with the other skin test antigens, either on the patient's back or on the volar surface of the forearm. The patient should be placed in a comfortable position before the testing is begun. For the prick test, a sharp needle is used to puncture the skin, but not to draw blood. If the scratch test is used, carefully break or scratch the skin with a sterile scarifier. Do not draw blood. Each scratch should be about 2 mm - 4 mm in length. A small drop of the histamine base 1 mg/mL (Histamine Phosphate 2.75 mg/mL) is placed on the abraded skin site no closer than 4 or 5 cm from an adjacent test site. Some physicians prefer to place the solution on the test area and then prick through the drop with a sharp needle.
Route of Administration: Parenteral
Histamine prevented monocytic apoptosis induced by serum deprivation, CD95/Fas ligation, or dexamethasone in a dose- and time-dependent fashion. The inhibitory effects of histamine on monocytic apoptosis were blocked by an H2R antagonist, and mimicked by an H2R agonist. Histamine also up-regulated the expression of Bcl-2 and Mcl-1, and inhibited the activation of caspase-3. The culture supernatants from histamine-treated monocytes inhibited monocytic apoptosis, which was partly reversed by the removal of IL-10. Monocytes cultured with anti-IL-10 mAb and histamine did not exhibit an inhibitory effect on apoptosis. The histamine-induced anti-apoptotic effect was attenuated when monocytes were cultured in the presence of a cAMP inhibitor.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:17:19 GMT 2023
Edited
by admin
on Fri Dec 15 17:17:19 GMT 2023
Record UNII
3POA0Q644U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HISTAMINE DIHYDROCHLORIDE
DASH   EMA EPAR   EP   MI   USAN   USP-RS  
USAN  
Official Name English
HISTAMINE DIHYDROCHLORIDE [USAN]
Common Name English
PEREMIN
Brand Name English
HISTAMINE HYDROCHLORIDE [MART.]
Common Name English
1H-IMIDAZOLE-5-ETHANAMINE, HYDROCHLORIDE (1:2)
Systematic Name English
Histamine hydrochloride [WHO-DD]
Common Name English
HISTAMINE DIHYDROCHLORIDE [USP-RS]
Common Name English
2-(4-IMIDAZOLYL)ETHYLAMINE DIHYDROCHLORIDE
Systematic Name English
1H-IMIDAZOLE-4-ETHANAMINE DIHYDROCHLORIDE
Systematic Name English
CEPLENE
Brand Name English
HISTAMINE DIHYDROCHLORIDE [EP MONOGRAPH]
Common Name English
HISTAMINE DIHYDROCHLORIDE [EMA EPAR]
Common Name English
ALLERGEN SCRATCH EXTRACT POSITIVE CONTROL 'TORII' HISTAMINE DIHYDROCHLORIDE
Brand Name English
HISTAMINUM HYDROCHLORICUM [HPUS]
Common Name English
HISTAMINE DIHYDROCHLORIDE [MI]
Common Name English
HISTAMINUM HYDROCHLORICUM
HPUS  
Common Name English
NSC-257873
Code English
HISTAMINE HYDROCHLORIDE
MART.   WHO-DD  
Systematic Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS CEPLENE (AUTHORIZED: LEUKEMIA, MYELOID, ACUTE)
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
EU-Orphan Drug EU/3/05/272
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
NCI_THESAURUS C2139
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
WHO-ATC L03AX14
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
WHO-VATC QL03AX14
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
Code System Code Type Description
JAPANESE REVIEW
ALLERGEN SCRATCH EXTRACT POSITIVE CONTROL "TORII" HISTAMINE DIHYDROCHLORIDE
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY APPROVED SEPTEMBER 2015
RS_ITEM_NUM
1309009
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
SMS_ID
100000089203
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
FDA UNII
3POA0Q644U
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
WIKIPEDIA
Histamine dihydrochloride
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
EVMPD
SUB12022MIG
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
MERCK INDEX
m6026
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL90
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
PUBCHEM
5818
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
NSC
257873
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
NCI_THESAURUS
C1734
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
EVMPD
SUB14108MIG
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
DRUG BANK
DBSALT002193
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
CAS
56-92-8
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID1058767
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
RXCUI
142136
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-298-4
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
DAILYMED
3POA0Q644U
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
PRIMARY
RXCUI
350466
Created by admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
ALTERNATIVE
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY